Autoantibodies with enzymatic properties in human autoimmune diseases

Journal of Autoimmunity

Volumn 37, Issue 2, 2011, Pages 144-150

  Wootla, Bharath ^a   Lacroix Desmazes, Sébastien ^c,d   Warrington, Arthur E ^a   Bieber, Allan J ^a   Kaveri, Srini V ^c,d   Rodriguez, Moses ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Abzymes; Autoantibodies; Autoimmunity; Catalytic antibodies

Indexed keywords

AMYLOID BETA PROTEIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CATALYTIC ANTIBODY; DNA ANTIBODY; ENZYME ANTIBODY; GLUCOSE REGULATED PROTEIN 94; HYDROLASE; IMMUNOGLOBULIN M; MYELIN BASIC PROTEIN; PROTHROMBIN; RNA ANTIBODY; THYROGLOBULIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALZHEIMER DISEASE; ANTIBODY ISOLATION; AUTOIMMUNE DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNE THYROIDITIS; BACTERICIDAL ACTIVITY; DIABETES MELLITUS; ENZYME KINETICS; HASHIMOTO DISEASE; HEMOPHILIA A; HUMAN; IMMUNOTHERAPY; KIDNEY GRAFT REJECTION; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, CATALYTIC; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; HUMANS; HYDROLYSIS; IMMUNOTHERAPY;

EID: 80052650654     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.05.007     Document Type: Review

References (79)

1. Pauling L. Chemical achievement and hope for the future. Am Scientist 1948, 36:51.
2. Pollack S.J., Jacobs J.W., Schultz P.G. Selective chemical catalysis by an antibody. Science 1986, 234:1570.
3. Tramontano A., Janda K.D., Lerner R.A. Catalytic antibodies. Science 1986, 234:1566.
4. Kalaga R., Li L., O'Dell J.R., Paul S. Unexpected presence of polyreactive catalytic antibodies in IgG from unimmunized donors and decreased levels in rheumatoid arthritis. J Immunol 1995, 155:2695-2702.
5. Paul S., Lan L., Kalaga R., O'Dell J., Dannenbring R.E., Swindells S., et al. Characterization of thyroglobulin-directed and polyreactive catalytic antibodies in autoimmune disease. J Immunol 1997, 159:1530-1536.
6. Planque S., Bangale Y., Song X.T., Karle S., Taguchi H., Poindexter B., et al. Ontogeny of proteolytic immunity: IgM serine proteases. J Biol Chem 2004.
7. Kanyshkova T.G., Semenov D.V., Khlimankov D., Buneva V.N., Nevinsky G.A. DNA-hydrolyzing activity of the light chain of IgG antibodies from milk of healthy human mothers. FEBS Lett 1997, 416:23-26.
8. Kit Y.-Y., Semenov D.V., Nevinsky G.A. Phosphorylation of different human milk proteins by human catalytic secretory immunoglobulin A. Biochem Molec Biol Intl 1996, 39:521-527.
9. Wentworth J.P., McDunn J.E., Wentworth A.D., Takeuchi C., Nieva J., Jones T., et al. Evidence of antibody-catalyzed ozone formation in bacterial killing and inflammation. Science 2002, 298:2195-2199.
10. Friboulet A., Avalle B., Debat H., Thomas D. A possible role of catalytic antibodies in metabolism. Immunol Today 1999, 20:474-475.
11. Paul S., Volle D.J., Beach C.M., Johnson D.R., Powell M.J., Massey R.J. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 1989, 244:1158-1162.
12. Shuster A.M., Gololobov G.V., Kvashuk O.A., Bogomolova A.E., Smirnov I.V., Gabibov A.G. DNA hydrolyzing autoantibodies. Science 1992, 256:665-667.
13. Vlassov A., Florentz C., Helm M., Naumov V., Buneva V., Nevinsky G., et al. Characterization and selectivity of catalytic antibodies from human serum with RNase activity. Nucleic Acids Res 1998, 26:5243-5250.
14. Baranovskii A.G., Kanyshkova T.G., Mogelnitskii A.S., Naumov V.A., Buneva V.N., Gusev E.I., et al. Polyclonal antibodies from blood and cerebrospinal fluid of patients with multiple sclerosis effectively hydrolyze DNA and RNA. Biochemistry (Mosc) 1998, 63:1239-1248.
15. Li L., Paul S., Tyutyulkova S., Kazatchkine M.D., Kaveri S. Catalytic activity of anti-thyroglobulin antibodies. J Immunol 1995, 154:3328-3332.
16. Taguchi H., Planque S., Nishiyama Y., Symersky J., Boivin S., Szabo P., et al. Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 2008, 283:4714-4722.
17. Ponomarenko N.A., Durova O.M., Vorobiev, Aleksandrova E.S., Telegin G.B., Chamborant O.G., et al. Catalytic antibodies in clinical and experimental pathology: human and mouse models. J Immunol Methods 2002, 269:197-211.
18. Ponomarenko N.A., Durova O.M., Vorobiev, Belogurov A.A., Kurkova I.N., Petrenko A.G., et al. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A 2006, 103:281-286.
19. Ponomarenko N.A., Durova O.M., Vorobiev, Belogurov A.A., Telegin G.B., Suchkov S.V., et al. Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale. Immunol Lett 2006, 103:45-50.
20. Lacroix-Desmazes S., Bayry J., Kaveri S.V., Hayon-Sonsino D., Thorenoor N., Charpentier J., et al. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci U S A 2005, 102:4109-4113.
21. Lacroix-Desmazes S., Bayry J., Misra N., Horn M.P., Villard S., Pashov A., et al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med 2002, 346:662-667.
22. Lacroix-Desmazes S., Moreau A., Sooryanarayana, Bonnemain C., Stieltjes N., Pashov A., et al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 1999, 5:1044-1047.
23. Lacroix-Desmazes S., Wootla B., Dasgupta S., Delignat S., Bayry J., Reinbolt J., et al. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. J Immunol 2006, 177:1355-1363.
24. Wootla B., Nicoletti A., Patey N., Dimitrov J.D., Legendre C., Christophe O.D., et al. Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients. J Immunol 2008, 180:8455-8460.
25. Wootla B., Dasgupta S., Dimitrov J.D., Bayry J., Levesque H., Borg J.Y., et al. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol 2008, 180:7714-7720.
26. Wootla B., Christophe O.D., Mahendra A., Dimitrov J.D., Repesse Y., Ollivier V., et al. Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood 2010.
27. Gabibov A.G., Gololobov G.V., Makarevich O.I., Schourov D.V., Chernova E.A., Yadav R.P. DNA-hydrolyzing autoantibodies. Appl Biochem Biotechnol 1994, 47:293-302. Discussion 3.
28. Kozyr A.V., Kolesnikov A.V., Aleksandrova E.S., Sashchenko L.P., Gnuchev N.V., Favorov P.V., et al. Novel functional activities of anti-DNA autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases. Appl Biochem Biotechnol 1998, 75:45-61.
29. Gololobov G.V., Chernova E.A., Schourov D.V., Smirnov I.V., Kudelina I.A., Gabibov A.G. Cleavage of supercoiled plasmid DNA by autoantibody Fab fragment: application of the flow linear dichroism technique. Proc Natl Acad Sci USA 1995, 92:254-257.
30. Gololobov G.V., Bogomolova A.E., Iadav R.P., Ermolaeva M.V., Belostotskaia K.M., Prokaeva T.B., et al. Isolation and characteristics of catalytic antibodies to DNA in systemic lupus erythematosis. Biokhimiia 1993, 58:313-318.
31. Kozyr A.V., Kolesnikov A.V., Zelenova N.A., Sashchenko L.P., Mikhalap S.V., Bulina M.E., et al. Autoantibodies to nuclear antigens: correlation between cytotoxicity and DNA-hydrolyzing activity. Appl Biochem Biotechnol 2000, 83:255-268. Discussion 68-9, 97-313.
32. Lee E.J., Jang E.J., Lee E., Yu J., Chung H.Y., Jang Y.J. Cell-penetrating autoantibody induces caspase-mediated apoptosis through catalytic hydrolysis of DNA. Bioorg Med Chem 2007, 15:2016-2023.
33. Carter C.J. Alzheimer's disease: a pathogenetic autoimmune disorder caused by herpes simplex in a gene-dependent manner. Int J Alzheimers Dis 2010, 2010:140539.
34. Black R.S., Sperling R.A., Safirstein B., Motter R.N., Pallay A., Nichols A., et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010, 24:198-203.
35. Howe C.L., Mayoral S., Rodriguez M. Activated microglia stimulate transcriptional changes in primary oligodendrocytes via IL-1beta. Neurobiol Dis 2006, 23:731-739.
36. Morgan D. Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener Dis 2005, 2:261-266.
37. Wingerchuk D.M., Lucchinetti C.F., Noseworthy J.H. Multiple sclerosis: current pathophysiological concepts. Lab Invest 2001, 81:263-281.
38. Hafler D.A. Multiple sclerosis. J Clin Invest 2004, 113:788-794.
39. Weber M.S., Hemmer B., Cepok S. The role of antibodies in multiple sclerosis. Biochim Biophys Acta 2011, 1812:239-245.
40. Polosukhina D.I., Kanyshkova T.G., Doronin B.M., Tyshkevich O.B., Buneva V.N., Boiko A.N., et al. Hydrolysis of myelin basic protein by polyclonal catalytic IgGs from the sera of patients with multiple sclerosis. J Cell Mol Med 2004, 8:359-368.
41. Belogurov A.A., Kurkova I.N., Misikov V.K., Suchkov S.V., Telegin G.B., Alekhine A.I., et al. Substrate specificity of catalytic autoantibodies in neurodegenerative processes. Dokl Biochem Biophys 2007, 413:61-64.
42. Belogurov A.A., Kurkova I.N., Friboulet A., Thomas D., Misikov V.K., Zakharova M.Y., et al. Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol 2008, 180:1258-1267.
43. Green D., Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemastos 1981, 45(3):200-203.
44. Delgado J., Jimenez-Yuste V., Hernandez-Navarro F., Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003, 121:21-35.
45. Collins P.W., Hirsch S., Baglin T.P., Dolan G., Hanley J., Makris M., et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007, 109:1870-1877.
46. Castro O., Farber L.R., Clyne L.P. Circulating anticoagulants against factors IX and XI in systemic lupus erythematosus. Ann Intern Med 1972, 77:543-548.
47. Kyriakou D.S., Alexandrakis M.G., Passam F.H., Foundouli K., Matalliotakis E., Koutroubakis I.E., et al. Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. Eur J Gastroenterol Hepatol 2002, 14:1383-1387.
48. Largo R., Sigg P., von Felten A., Straub P.W. Acquired factor-IX inhibitor in a nonhaemophilic patient with autoimmune disease. Br J Haematol 1974, 26:129-140.
49. Ozsoylu S., Ozer F.L. Acquired factor IX deficiency. A report of two cases. Acta Haematol 1973, 50:305-314.
50. Roberts H.R. Acquired inhibitors to factor IX. N Engl J Med 1970, 283:543-544.
51. Gouyon J.B., Seiller F., Deries X., Alison M., Lorenzini J.L., Devilliers E. Inhibitors of factors VIII and IX in a child with Henoch-Schonlein syndrome. Am J Pediatr Hematol Oncol 1985, 7:376-377.
52. Reussi C., Altman R., Rouvier J., Maino R. Combined factor VIII and IX inhibitors in a girl. Thromb Diath Haemorrh 1966, 16:549-558.
53. Paul S., Li L., Kalaga R., Wilkins-Stevens P., Stevens F.J., Solomon A. Natural catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL fragments. J Biol Chem 1995, 270:15257-15261.
54. Baranovskii A.G., Ershova N.A., Buneva V.N., Kanyshkova T.G., Mogelnitskii A.S., Doronin B.M., et al. Catalytic heterogeneity of polyclonal DNA-hydrolyzing antibodies from the sera of patients with multiple sclerosis. Immunol Lett 2001, 76:163-167.
55. Saveliev A.N., Ivanen D.R., Kulminskaya A.A., Ershova N.A., Kanyshkova T.G., Buneva V.N., et al. Amylolytic activity of IgM and IgG antibodies from patients with multiple sclerosis. Immunol Lett 2003, 86:291-297.
56. Nardi M., Tomlinson S., Greco M.A., Karpatkin S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell 2001, 106:551-561.
57. Tawfik D.S., Chap R., Green B.S., Sela M., Eshhar Z. Unexpectedly high occurence of catalytic antibodies in MLR/lpr and SLJ mice immunized with a transition-state analog: is there a linkage to autoimmunity. Proc Natl Acad Sci USA 1995, 92:2145-2149.
58. Meroni P.L., Shoenfeld Y. Systemic lupus erythematosus and the SLE galaxy. Autoimmun Rev 2010, 10:1-2.
59. Mozes E., Sharabi A. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus. Autoimmun Rev 2010, 10:22-26.
60. Doria A., Zen M., Canova M., Bettio S., Bassi N., Nalotto L., et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010, 10:55-60.
61. Fauchais A.L., Martel C., Gondran G., Lambert M., Launay D., Jauberteau M.O., et al. Immunological profile in primary Sjogren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun Rev 2010, 9:595-599.
62. Alevizos I., Illei G.G. MicroRNAs in Sjogren's syndrome as a prototypic autoimmune disease. Autoimmun Rev 2010, 9:618-621.
63. Lu Q., Renaudineau Y., Cha S., Ilei G., Brooks W.H., Selmi C., et al. Epigenetics in autoimmune disorders: highlights of the 10th Sjogren's syndrome symposium. Autoimmun Rev 2010, 9:627-630.
64. Youinou P., Haralampos M. Moutsopoulos: a lifetime in autoimmunity. J Autoimmun 2010, 35:171-175.
65. Mackay I.R., Leskovsek N.V., Rose N.R. The odd couple: a fresh look at autoimmunity and immunodeficiency. J Autoimmun 2010, 35:199-205.
66. Kontaki E., Boumpas D.T. Innate immunity in systemic lupus erythematosus: sensing endogenous nucleic acids. J Autoimmun 2010, 35:206-211.
67. Wiik A.S., Hoier-Madsen M., Forslid J., Charles P., Meyrowitsch J. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 2010, 35:276-290.
68. Youinou P., Pers J.-O., Gershwin M.E., Shoenfeld Y. Geo-epidemiology and autoimmunity. J Autoimmun 2010, 34:J163-J167.
69. Shapira Y., Agmon-Levin N., Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 2010, 34:J168-J177.
70. Brooks W.H., Le Dantec C., Pers J.-O., Youinou P., Renaudineau Y. Epigenetics and autoimmunity. J Autoimmun 2010, 34:J207-J219.
71. Chang C. The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 2010, 34:J234-J246.
72. Chang C., Gershwin M.E. Drugs and autoimmunity - a contemporary review and mechanistic approach. J Autoimmun 2010, 34:J266-J275.
73. Chen M., Daha M.R., Kallenberg C.G.M. The complement system in systemic autoimmune disease. J Autoimmun 2010, 34:J276-J286.
74. Chandran V., Raychaudhuri S.P. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010, 34:J314-J321.
75. Schilder A.M. Wegener's granulomatosis vasculitis and granuloma. Autoimmun Rev 2010, 9:483-487.
76. Rubtsov A.V., Rubtsova K., Kappler J.W., Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev 2010, 9:494-498.
77. Ansari A.A., Gershwin M.E. Navigating the passage between Charybdis and Scylla: recognizing the achievements of Noel Rose. J Autoimmun 2009, 33:165-169.
78. Mackay I.R. Clustering and commonalities among autoimmune diseases. J Autoimmun 2009, 33:170-177.
79. Yaniv I., Ash S., Farkas D.L., Askenasy N., Stein J. Considering of strategies for hematopoietic cell transplantation. J Autoimmun 2009, 33:255-259.